Clinical trials: in Mexico
Coginitive Dysfunction
The Effects, Usability, Satisfaction, Barriers, and Benefits of a Remote, Multidomain Website-based Intervention to Prevent Cognitive Decline in Older Adults
Mexico exhibits a high prevalence of dementia, exceeding 8%, and it is estimated that by 2050 around 3.5 million older adults will be living with this condition.
- Trial name
- MeMoHealthCogR (NCT07668440)
- Testing
- Multi-domain intervention: Physical activity, cognitive training, and educational program through a website
- Where
- Mexico
- Volunteers
- 71 people
- Sponsor
- Instituto Mexicano del Seguro Social
Gestational Diabetes, Overweight and Obesity
Educational Intervention in the First 18 Months of Life to Prevent/Manage Obesity of Children After Gestational Diabetes
In order to evaluate the effect of an educational intervention on mothers with gestational diabetes and their offspring in the first 18 months of life, The intervention will be applied to mothers with gestational diabetes, and a…
- Trial name
- NCT04493177
- Testing
- Educational intervention, Conventional treatment Guia de Practica Clinica IMSS-029-08
- Where
- Mexico
- Volunteers
- 645 people, healthy volunteers welcome
- Sponsor
- Instituto Mexicano del Seguro Social
Systemic Lupus Erythematosus
A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of RO7507062 in participants with systemic lupus erythematosus (SLE).
- Trial name
- NCT05835986
- Testing
- RO7507062, Tocilizumab
- Where
- 18 sites in Colombia, France and 11 more
- Volunteers
- 70 people
- Sponsor
- Hoffmann-La Roche
Locally Advanced or Metastatic Breast Cancer
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Phesgo after induction therapy with Phesgo plus taxane in participants with human…
- Trial name
- NCT05296798
- Testing
- Phesgo, Giredestrant, Docetaxel
- Where
- 198 sites in United States, Argentina and 27 more
- Volunteers
- 922 people
- Sponsor
- Hoffmann-La Roche
Bronchiolitis, Wheezing
Nebulized 3% Hypertonic Saline Solution Treatment of Bronchiolitis in Infants
Determine the efficacy of nebulized salbutamol/hypertonic saline combination in moderate to severe bronchiolitis.
- Trial name
- NCT02233985
- Testing
- 0.9% Sodium Chloride, 3% Sodium Chloride
- Where
- Mexico
- Volunteers
- 64 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Coronary Artery Disease, Erectile Dysfunction
Pudendal Atherosclerosis by IVUS-NIRS in Men With Coronary Artery Disease
This prospective, single-center, exploratory study will evaluate the association between atherosclerotic and lipid plaque burden in the internal pudendal arteries, assessed by intravascular ultrasound and near-infrared…
- Conditions
- Coronary Artery Disease, Erectile Dysfunction, Atherosclerosis
- Trial name
- PUDENDAL-NIRS (NCT07856199)
- Testing
- Selective Pudendal Angiography, Pudendal IVUS-NIRS Imaging
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Hospital Central Militar
Substance Abuse Disorder, Addiction
Cross-sectional Functional Stratification Based on Psychometric Profiling and Machine Learning in Patients With Substance Use Disorders (SUD)
Substance use disorders (SUDs) show considerable clinical heterogeneity that limits the usefulness of traditional categorical diagnoses.
- Conditions
- Substance Abuse Disorder, Addiction, Clinical Stratification, Substance-related Disorders
- Trial name
- SISAP-TUS (NCT07590154)
- Testing
- No intervention (observational only)
- Where
- Mexico
- Volunteers
- 155 people
- Sponsor
- Lauro Gutiérrez Castro
Myelofibrosis, Anemia
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
The main aim of this study is to find out how well elritercept works to improve anemia in participants with myelofibrosis (MF) who are taking ruxolitinib when compared to placebo.
- Trial name
- ELRISE MF (NCT07623161)
- Testing
- Elritercept
- Where
- 195 sites in United States, Argentina and 29 more
- Volunteers
- 324 people
- Sponsor
- Takeda
Respiratory Syncytial Virus Infections
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
The purpose of this study is: To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately…
- Trial name
- RSV OA=ADJ=012 (NCT06534892)
- Testing
- RSVPreF3 OA vaccine
- Where
- 251 sites in United States, Australia and 15 more
- Volunteers
- 10,212 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Heart Failure
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo.
- Trial name
- HERMES (NCT05636176)
- Testing
- Ziltivekimab
- Where
- 1,013 sites in United States, Argentina and 44 more
- Volunteers
- 4,874 people
- Sponsor
- Novo Nordisk A/S
Atypical Hemolytic Uremic Syndrome
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
This study aims to evaluate the efficacy and safety of crovalimab in pediatric participants with aHUS.
- Trial name
- COMMUTE-p (NCT04958265)
- Testing
- Crovalimab
- Where
- 20 sites in United States, Belgium and 8 more
- Volunteers
- 41 people
- Sponsor
- Hoffmann-La Roche
Neuromyelitis Optica Spectrum Disorder, NMOSD
A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
This study will primarily evaluate the pharmacokinetics of satralizumab in pediatric patients aged 2-11 years with anti-aquaporin-4 (AQP4) antibody seropositive neuromyelitis optica spectrum disorder (NMOSD).
- Trial name
- SAkuraSun (NCT05199688)
- Testing
- Satralizumab
- Where
- 14 sites in United States, Argentina and 7 more
- Volunteers
- 8 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer, Non-squamous, Non-small Cell
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including…
- Trial name
- NCT06151574
- Testing
- zongertinib, pembrolizumab, cisplatin
- Where
- 163 sites in United States, Argentina and 24 more
- Volunteers
- 428 people
- Sponsor
- Boehringer Ingelheim
Multiple Sclerosis
Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)
- Trial name
- ENSURE-1 (NCT05134441)
- Testing
- IMU-838 tablets
- Where
- 103 sites in United States, Albania and 15 more
- Volunteers
- 1,121 people
- Sponsor
- Immunic AG
Obesity
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines.
- Trial name
- REDEFINE 1 (NCT05567796)
- Testing
- Cagrilintide, Semaglutide
- Where
- 256 sites in United States, Argentina and 21 more
- Volunteers
- 3,400 people
- Sponsor
- Novo Nordisk A/S
Locally Advanced Cervical Cancer
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have…
- Trial name
- eVOLVECervical (NCT06079671)
- Testing
- Volrustomig
- Where
- 205 sites in United States, Brazil and 17 more
- Volunteers
- 800 people
- Sponsor
- AstraZeneca
Overweight, Obesity
Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets
The purpose of this study is to assess semaglutide's impact on daily life from participants and physicians experience.
- Trial name
- NCT07850765
- Testing
- Semaglutide
- Where
- 6 sites in Israel, Mexico and 4 more
- Volunteers
- 1,260 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study.
- Trial name
- NCT07253285
- Testing
- Cagrilintide, Semaglutide
- Where
- 121 sites in United States, Australia and 24 more
- Volunteers
- 460 people
- Sponsor
- Novo Nordisk A/S
Community-acquired Pneumonia
AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia
This is an international, open-label, stratified randomized controlled trial with Bayesian adaptive stopping rules to compare the effects of therapeutic-dose heparin vs.
- Trial name
- ATTACC-CAP (NCT05848713)
- Testing
- Heparin
- Where
- 68 sites in United States, Brazil and 2 more
- Volunteers
- 4,000 people
- Sponsor
- University of Manitoba
Non-small Cell Lung Cancer (NSCLC)
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT07361497
- Testing
- Pumitamig, Durvalumab
- Where
- 260 sites in United States, Argentina and 30 more
- Volunteers
- 850 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.